Sort   by:  
 Page size 
UnknownPrognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Not available
S-EPMC4981975 | biostudies-literature
UnknownValidation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Not available
S-EPMC3871512 | biostudies-literature
UnknownIntrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.
Not available
S-EPMC4397278 | biostudies-literature
TranscriptomicsGene expression profiling of invasive breast cancer events from the tamoxifen prevention trial
Gene expression profiling of invasive breast cancer events from the tamoxifen prevention trial validates low estrogen receptor mRNA level as the main determinant of tamoxifen resistance in estrogen receptor positive breast cancer. In NSABP Breast Cancer Prevention Trial (BCPT), tamoxifen reduced th...
ORGANISM(S): Homo sapiens 
2011-12-08 | E-GEOD-12665 | biostudies-arrayexpress
TranscriptomicsGene expression profiling of formalin fixed paraffin embedded tumor tissue identifies gastric cancer patients who are at high risk after curative surgery plus adjuvant chemoradiotherapy
Gastric cancer is the second most common cause of cancer-related death worldwide. Up to 80% of patients who undergo curative surgical resection develop locoregional or distant recurrence. A recent large-scaled meta-analysis on 3,838 patients from 17 trials has demonstrated survival benefit from ad...
ORGANISM(S): Homo sapiens 
2014-03-01 | E-GEOD-26253 | biostudies-arrayexpress
UnknownEstrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Not available
S-EPMC3208536 | biostudies-literature
UnknownAdjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Not available
S-EPMC3341142 | biostudies-literature
UnknownRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Not available
S-EPMC4086638 | biostudies-literature
GenomicPrediction of Trastuzumab Benefit in Adjuvant Breast Cancer: NSABP B31

Background
National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tu...

phs000826 | dbGaP
UnknownDefinitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Not available
S-EPMC3757290 | biostudies-literature
Sort   by:  
 Page size